Board of Directors
Jean Hoffman (Chairman) has led Putney since founding the Company in 2006. Prior to Putney, she founded Q Street Advisors, focused on the global generic and API pharma sectors. She was the founder, chairman and CEO of Newport Strategies, the world leader in licensing and business development databases for global generic pharma. Ms. Hoffman sold Newport to ThomsonReuters (NYSE: TRI) in 2004. Ms. Hoffman's career spans 30 years of leadership and strategy in the global pharmaceutical sector.
Shyam Bhartia, who has served on Putney's Board since 2007, is a leading industrialist of India with experience in the pharmaceutical and specialty chemicals, food, oil and gas, aerospace and IT sectors. Mr. Bhartia is the chairman and managing director of Jubilant Organosys Ltd., an integrated pharmaceutical industry player and the largest custom research and manufacturing services (CRAMS) business in India. Jubilant employs over 5800 people, over 1400 of whom are based in North America. Mr. Bhartia was instrumental in expanding the company in the U.S. by acquiring Hollister-Stier and Tri-Gen (now Cadista).
E. Thomas Corcoran served as President of Fort Dodge Animal Health, a division of Wyeth, from 1995 until his retirement in 2008. Mr. Corcoran joined Fort Dodge in 1985 as Division President and was promoted to Vice President in 1993. During his 23 year tenure, Corcoran led Fort Dodge’s growth from a $28 million domestic company into a global business of over $1 billion in annual revenues.
Mr. Corcoran’s leadership in the animal health industry was recognized with the Animal Pharm Lifetime Achievement Award in 2007, the American Veterinary Distributors Association’s Lifetime Achievement Award in 2008, and the Iron Paw Award from the Kansas City Animal Health Corridor in 2008. In 2008, he was also awarded the Distinguished Alumni Award from the University of South Alabama, where he currently serves on the Board of Trustees. Mr. Corcoran continues his commitment to the animal health industry as a member of the board of directors for both Animal Health International, Inc. and Phibro Animal Health.
Jim Datin joined Safeguard Scientifics, Inc. (NYSE: SFE), a provider of growth capital and operational support for entrepreneurial and innovative life sciences and technology companies, in 2005. As Executive Vice President and Managing Director of the Life Sciences Group at Safeguard, Mr. Datin drives partnership opportunities in molecular and point-of-care diagnostics, medical devices, regenerative medicine, and specialty pharmaceuticals. His 25+ years of executive leadership experience includes positions as CEO of Touchpoint Solutions, Inc., Group President of Dendrite International, and Group Director at GlaxoSmithKline. Over the course of his career, Mr. Datin has completed approximately 50 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements.
Bruce Downey is a partner in NewSpring Health Capital II, a private equity fund investing in healthcare companies within the specialty pharmaceuticals, healthcare services and medical device sectors. Previously, Mr. Downey was Chairman of the Board and CEO of Barr Pharmaceuticals, Inc. During his fourteen year tenure as CEO, Mr. Downey increased annual revenues from $60 million to over $2.5 billion and grew Barr to become the fourth largest global generic drug company. Barr was acquired in 2008 by Teva Pharmaceutical Industries, Ltd. for approximately $9 billion.
Prior to joining Barr, Mr. Downey was a capital partner in Winston & Strawn, an international law firm focused on business-related litigation and regulatory matters. He received his law degree cum laude from Ohio State University and began his legal career in the Honors Program at the U.S. Department of Justice. In 2006 and 2007, Mr. Downey served as the Chairman of the Board for the Generic Pharmaceutical Association (GPhA), the trade association for the generic pharmaceutical industry.
Barry Edwards, a Director since 2007, is a consultant serving manufacturer, distributor and investment firm clients with respect to the U.S. generic/specialty pharmaceutical market. Mr. Edwards was previously CEO of Impax Laboratories (IPXL), a public, technology based specialty pharmaceutical company. During his tenure at Impax, Mr. Edwards grew the company to $200 million in sales and was a key player in raising $500 million. Prior to Impax, Mr. Edwards spent more than 20 years with Teva, where his last position was vice president of marketing and business development.
B. Lance Sauerteig is president of BLS Strategic Capital, a company providing wealth management and investment advisory services, and Tortoise Capital Partners LLC, a real estate investment company. Mr. Sauerteig is a director of Chemwerth, Inc. and United Aluminum Corporation. He was president of First Spring Corporation, a NY based private family management and investment company from 1986-1994. Prior to that he was an attorney in private practice, with Bergman, Horowitz & Reynolds, where he served as associate, partner and managing partner. Mr. Sauerteig is admitted to the bar in Connecticut and Pennsylvania.